January 21, 2012
Fact Sheet 475).
Tenofovir is a nucleotide analog reverse transcriptase inhibitor, or nuke. These drugs stop HIV from multiplying by preventing the reverse transcriptase enzyme from working. This enzyme changes HIV's genetic material (RNA) into the form of DNA. This has to occur before HIV's genetic code is inserted into an infected cell's genetic codes.
Tenofovir was approved in 2001 as an antiretroviral drug (ARV) for people with HIV infection. In 2010 it was approved for use by people between 12 and 18 years old. In 2011 it was approved for use in children ages 2 to 12. It has not been carefully studied in people older than age 65. In US treatment guidelines (see Fact Sheet 404), tenofovir is listed as a preferred drug for people just starting ART.
There are no absolute rules about when to start ART. You and your health care provider should consider your CD4 cell count, your viral load, any symptoms you are having, and your attitude about taking ART. Fact Sheet 404 has more information about guidelines for the use of ARVs.
Be sure to let your health care provider know if you have any kidney problems. People with kidney damage may need to take a reduced dose of tenofovir.
If you take tenofovir with other ARVs, you can reduce your viral load to extremely low levels, and increase your CD4 cell counts. This should mean staying healthier longer.
Tenofovir may also help control Hepatitis B. However, Hep B got much worse in some people who were taking tenofovir and then stopped taking it. Get tested for hepatitis B before you start taking tenofovir to treat HIV. If you have hepatitis B and stop taking tenofovir, your health care provider should carefully monitor your liver function for several months.
Tenofovir is also being studied for the prevention of HIV infection. Gilead hopes that just one pill a day will be effective.
Fact Sheet 126 for more information on resistance.
Sometimes, if your virus develops resistance to one drug, it will also have resistance to other ARVs. This is called "cross-resistance." However, tenofovir seems to have very little cross resistance with other ARVs.
Resistance can develop quickly. It is very important to take ARVs according to instructions, on schedule, and not to skip or reduce doses.
The most common side effects of tenofovir are nausea, vomiting and loss of appetite. Tenofovir can ause kidney damage. Creatinine levels should be monitored in people taking tenofovir. Tenofovir can also damage the liver. People taking tenofovir should have their liver health monitored.
Tenofovir can reduce bone mineral density (see Fact Sheet 557). Calcium or vitamin D supplements may be helpful. This is especially true for people with osteopenia or osteoporosis. This is important for young people because bone density normally increases during this period.
Tenofovir results in higher blood levels of didanosine (Videx). ddI and tenofovir should not be used together, especially in patients with a high viral load and a low CD4 count. Serious ddI side effects may result.
Tenofovir blood levels increase if it is taken with the protease inhibitors atazanavir (Reyataz) and lopinavir/ritonavir (Kaletra). This can increase the risk of tenofovir side effects. Tenofovir decreases blood levels of atazanavir. Ritonavir should be taken when atazanavir is taken with tenofovir.
Tenofovir does not affect blood levels of methadone, ribavirin or adefovir. There is no known interaction between tenofovir and buprenorphine.
Three regimens should normally not be used without careful analysis or extra ARVs:
Tenofovir is eliminated by the kidneys. It is not metabolized in the liver, so it is not expected to interact with many other drugs. However, medications with names that end in "-ovir," such as acyclovir and ganciclovir, may interact with tenofovir.
Tenofovir should be used as part of combination antiretroviral therapy (ART) against HIV. It is normally used along with a nucleoside analog reverse transcriptase inhibitor (nuke) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor.
This article was provided by AIDS InfoNet. Visit AIDS InfoNet's website to find out more about their activities and publications.